Drug Profile
MBP 134
Alternative Names: MBP-134; pan-Ebola - Mapp BiopharmaceuticalLatest Information Update: 12 Dec 2022
Price :
$50
*
At a glance
- Originator Adimab; Albert Einstein College of Medicine
- Developer Mapp Biopharmaceutical
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ebola virus infections